Zenas BioPharma (ZBIO) Cash & Current Investments (2023 - 2026)

Zenas BioPharma's Cash & Current Investments history runs 4 years deep, the most recent figure standing at $717.2 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 129.59% year-over-year to $717.2 million; the TTM figure through Mar 2026 stood at $717.2 million (up 129.59% YoY), while the FY2025 annual figure was $343.2 million, down 2.16% from the prior year.
• Cash & Current Investments was $717.2 million for Q1 2026 at Zenas BioPharma, up from $343.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $717.2 million in Q1 2026 to a low of $37.2 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $272.6 million across 4 years, with a median of $290.9 million in 2025.
• Biggest YoY gain for Cash & Current Investments was 738.83% in 2025; the steepest drop was 19.23% in 2025.
• A 4-year view of Cash & Current Investments shows it stood at $56.9 million in 2023, then surged by 516.93% to $350.8 million in 2024, then slipped by 2.16% to $343.2 million in 2025, then soared by 108.98% to $717.2 million in 2026.
• The last three Cash & Current Investments figures came in at $717.2 million (Q1 2026), $343.2 million (Q4 2025), and $290.9 million (Q3 2025), per Business Quant data.